GSK strikes take care of Oxford for most cancers jabs
Pharmaceutical giant GSK has inked a deal with the University of Oxford that will see it pump tens of millions of pounds into research for cancer vaccines.
The FTSE 100 firm said under a collaboration with the university it would invest £50m over three years to find out whether cancers could be prevented from developing with jabs.
It said most cancers take years or decades to develop from normal cells and as a result drugs could be developed to recognise ‘precancerous’ ones and allow the immune system to eliminate them before they progress.
Tony Wood, GSK’s chief scientific officer, said: ‘We aim to generate key insights for people at risk of developing cancer.’
Investing for the future: Boss Emma Walmsley is pushing ahead with a strategy to boost GSK’s fortunes through lucrative cancer treatments and vaccines
The collaboration comes as boss Emma Walmsley pushes ahead with a strategy to boost GSK’s fortunes through lucrative cancer treatments and vaccines.
DIY INVESTING PLATFORMS
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.
